




MAPS
SHARING KNOWLEDGE

Next Gems

October 2022



Marco Ciscato

Chairman

Founder of Maps.

He graduated in Software Engineering at University of Bologna and started his career as software engineer at DS Data Systems. During the first phase of Maps he worked in the technical area. After obtaining a Master in Business Administration at CUOA in Vicenza, at first he moved from the technical area to strategic customer management and then to internal organization, finance & control and strategic development.



Gian Luca Cattani

R&D Director

Degree in Mathematics cum laude at the University of Parma; MSc and PhD in Computer Science at the University of Aarhus (Denmark); Master in Technology and Innovation Management at the Bologna Business School of the University of Bologna. He was a researcher in Logic and Semantics of Computation at the University of Cambridge (UK). He is the author of several scientific publications in Theoretical Computer Science. For twenty years he has been involved in software development Bespoke solution for complex organizations. In MAPS since 2008, he was appointed R&D Director in 2017.



The Challenge

The challenge for Maps is **extracting business value** from **data**



What we do

We develop **data-driven products** that help our customers in taking better decisions and redesign their business models



Scalability


Our strategy is to **deploy** each of our Proprietary Products to **many customers**




Focus

In the Digital Transformation Market we are focusing on **healthcare**, **energy** and **ESG**

Total Revenues



EBITDA



Revenues Composition




2018

CAGR 18-21: 50%



2021



2022 H1

What we do

 **Healthcare**

 **Energy**

 **ESG**



In the **Healthcare market**, we decided to address a new disruptive digital trend, the **Patient Experience**, which has not been fully exploited yet.

Our mission is to improve the patient experience by **providing patient-centered products** to hospitals, outpatient care facilities and local health authorities.

The Patient Experience areas addressed by our products

Patient Journey



Data Analysis



Patient care



Patient diagnostic



Patient Journey

Data analysis

Patient Care

Patien Diagnostic

ZeroCoda & MR You



ZEROCODA
PATIENT JOURNEY SOLUTION



MR YOU
PATIENT JOURNEY SOLUTION

A **suite of apps** both mobile and web, kiosks, and digital signage to **seamlessly streamline access to healthcare services**

36 million patients

accessed healthcare services in 2021
using ZeroCoda and MrYou

580,000 waiting hours saved
in accessing healthcare services in 2021





Patient Journey

Data analysis

Patient care

Patien Diagnostic

Clinika



A **Decision Support System**, based on MAPS patented method for clinical text understanding, designed to **reduce waiting times** by analyzing data and helping healthcare providers in using appropriately diagnostic resources

16 million

diagnostic test requests and referrals analyzed in 2021

		YEAR						
Referral Guideline	start	2011	2012	2013	2014	2015	2016	2017
Neuro MRI	2012	29%	61%	67%	68%	71%	71%	71%
Osteoarticular MRI	2013	28%	64%	70%	71%	75%	73%	74%
Colonoscopy	2014	27%	54%	57%	59%	65%	70%	70%
Gastroscopy	2014	16%	38%	43%	44%	47%	50%	50%
Neurological CT Scan	2015	17%	41%	45%	46%	47%	47%	46%
Osteoarticular CT Scan	2015	13%	32%	35%	42%	44%	52%	58%
Vascular EcoColorDoppler	2016	14%	31%	32%	34%	33%	35%	37%
Thyroid Pathology	2016	15%	36%	43%	45%	48%	52%	53%
Gastroenterological examination	2016	9%	17%	14%	19%	30%	32%	33%

Percentage of Appropriate Referral Requests, Measurements Taken Independently by a Customer LHA (AUSL)



Patient Journey

Data analysis

Patient care

Patient Diagnostic


Iasi SISWeb



A **configurable Electronic Health Record** system for Hospital Departments specifically designed **for managing the patient care process**

30,000

Healthcare professionals use SISWeb





Patient Journey

Data analysis

Patient care

Patient Diagnostic

Alchymia



A **product** for end-to-end efficient and error-free **management of laboratory test services**.


5.6 million

Laboratory referrals produced in 2021


Case study

Patient diagnostic

Patient journey



ZEROCODA
PATIENT JOURNEY SOLUTION



MR YOU
PATIENT JOURNEY SOLUTION




“Centro Prelievo Facile”

Alchymia has been combined with ZeroCoda and MrYou to provide a best-of-breed patient journey experience for laboratory diagnostics



The **Energy market** is facing a radical transformation. In a context previously characterized by a few production points capable of supplying the necessary energy (few-to-many), **new forms of renewable energy producers** are now being established, **changing the network infrastructure (many-to-many)** making it much more complex to be managed

To achieve efficiency and resilience in this new setting, there is a **need for cooperation** by all actors and **smart management of energy assets**. A new market of so-called **flexibility services** is arising, and **Energy Communities** will play a key role in it



Moreover, the **increase in the cost of energy** has put additional **pressure on energy consumers** who now urgently **need to address** in the **smartest** possible way their **energy needs**, also by leveraging a coordinated set of different energy sources



In this new context, **our products** provide **Energy efficiency at site level** and **optimal management of Energy Communities** with a high-degree of intelligent automation

ROSE



A **smart software** product for:

- Community Design
- Community management
- Energy efficiency optimization
- Community administration
- Participants engagement and distribution of rewards

What has been already achieved

Iren

4 years long contract to provide ROSE for the management of all the Energy Communities that IREN will develop

ENEL

Development of a predictive maintenance system

First established Italian Energy Community uses our solution

What's next

- **Breakeven** expected already **at 2022**
- **2.6B€** of EU funds **allocated by the Italian government** for the development of Energy Communities
- **Rising interest** for participation in Energy Communities by **shopping malls** and **industrial sites** due to increasing energy costs

In the **ESG**, our Proprietary Products improve the **digitalization of corporate data**:

- Measuring and communicating societal objectives and achievements of corporations and institutions
- Managing employees' objectives and achievements

An example of our ESG products

Gzoom



Structured Definition of Corporate Objectives and related Key Performance Indicators (KPI), Measurement and Communication of achievements

70 Italian public entities

measure their non-financial performances using Gzoom

Our results



Attitude in dealing with leaders

We have a long experience in dealing with customers that are leaders in their sectors

Maps leveraged this asset to understand market needs.

Strategic business unit

System Integration and Consulting is devoted to custom solutions. Fundamental for our past initial growth, and for the fulfillment of needs of strategic customers

Research & Solutions is dedicated to innovation and to the development of MAPS new Proprietary Products

Approach

Open Innovation

Collaborations and co-investments with market leaders and research centers



PHILIP MORRIS
INTERNATIONAL



POLITECNICO
MILANO 1863



Achievements - Business Model based on Proprietary Products

Advantages for Customers

Obtain answers to their needs thanks to already existing Maps' Proprietary Products.

They are serviced with immediately available tools, and don't have to wait for *ad-hoc* bespoke developments.

The answer to the individual need relies on experiences and investments made on many.

Advantages for Maps

Maps' business model is scalable since our Proprietary Products are designed to be deployed as-is for many different customers.

Customers that invest in ready-made solutions are prone to long term relationships, and to become loyal customers.


Long term relationships based on Proprietary Products lead to recurrent revenues.

Scalability and loyalty entails efficiency, and hence higher profitability.




Achievements - Business Model based on Proprietary Products


Revenues from Proprietary Products



Revenues from Recurrent Fees



Achievements – M&A



Focus – I-TEL acquisition

Offering

Focalization on Healthcare

- **Telemedicine**: patients living at home are monitored and can communicate with healthcare professionals, improving benefits for patients and reducing healthcare costs

- **Omnichannel** friendly and efficient **communication** between patients and healthcare service providers

Transactions

70% acquisition

Price: € 4.1 mln

€ 1.2 mln: Maps shares at € 5.05 per share

Cash Payment: € 2.9 mln at deal closing

EBITDAx: 7.0

Business Model

Based on **Proprietary Products**

- **High recurrent fees** (2021: 60%)
- **Loyal Customers**

Financial performance

Before acquisition (2021)

Revenues: € 2.3 mln

EBITDA: € 0.8 mln

Contribution margin: 60%

Synergies



I-TEL acquisition (and the following acquisition of Optimist), **supplement the patient journey offer line**, by providing new communication channels between patients and hospitals



Maps solutions will be **smarter and more useful** for decision makers, **analyzing conversational data generated by I-Tel solutions**



Focus – Energenius acquisition

Offering

Focalization on Energy

- **GEM Analytics**: Cloud solution for the monitoring, analysis, consumption modelling, technical management and maintenance of energy assets.

Business Model

Based on **Proprietary Products**

- **Revenue from Proprietary Products**: 62% (2021)

Financial performance

Before acquisition (2021)

Revenues: € 1.21 mln

EBITDA Adj.: € 0.3 mln

Transactions

51% acquisition

Price: € 0.84 mln

Cash Payment: € 0.84 mln at deal closing

Synergies



Energenius focus on **energy assets** and **energy efficiency** at industrial and shopping mall level **complements MAPS ROSE offering** at Energy Community level for a best-of-breed highly-scalable energy efficiency solution



Gem together with **Rose** will offer a **complete solution** with **distinctive features** that will help strengthen our market position



Achievements – 2022 H1 Results

€/1,000	2022 H1	1H 2021
Total Revenues	11,797	10,655
Internally generated fixed assets	1,233	852
Production Value	13,030	11,507
Operating Costs	(9,982)	(8,659)
EBITDA	3,048	2,848
Amortization & Depreciation	(1,288)	(1,175)
Not recurring costs	(136)	-
EBIT	1,624	1,673
Financial Management & Subsidiaries	(156)	(183)
EBT	1,469	1,489
Tax	62	172
Net Profit	1,530	1,661

€/1,000	2022 H1	2021
Fixed Assets	21,068	18,936
Inventory	5,658	3,601
Receivables	10,727	9,901
Payables	(2,584)	(2,489)
Operating Working Capital	13,801	11,013
Other Current assets & liability	(2,936)	(1,246)
Net Working Capital	10,865	9,767
Total Funds	(5,259)	(5,712)
Net Capital Invested	26,674	22,991
Shareholders' Equity	17,059	18,083
Long Term Debt	10,731	12,189
Short Term Debt	6,269	3,815
Cash	(7,385)	(11,097)
Net Financial Position	9,615	4,908
Total resources of financing	26,674	22,991

Total Revenues



Recurrent revenues from fees



EBITDA



NFP



Achievements – 2022 H1 Results

€ / 1.000	Healthcare	Energy	ESG	Custom Solution	1H 2022
Recurrent Fees	3,460	-	608	745	4,813
Services	3,541	421	591	2.133	6,687
Others Revenue	120	124	17	36	1,587
Total Revenues	7,122	545	1,216	2,914	11,797
Personnel Costs	(1,906)	(162)	(524)	(1,234)	(3,825)
Direct Services Costs	(1,204)	(6)	(186)	(315)	(1,710)
Total Operating Costs	(3,110)	(168)	(709)	(1,549)	(5,535)
Commercial Costs	(962)	(144)	(187)	(61)	(1,353)
R&D Costs	(663)	(347)	(131)	(93)	(1,233)
Internally Generated Fixed Assets	663	347	131	93	1,233
Administrative Costs	(1,142)	(104)	(150)	(463)	(1,860)
EBITDA	1,908	129	169	842	3,048
EBITDA Margin	26.8%	23.7%	13.9%	28.9%	25.8%
Contribution Margin	3,892	253	490	1,330	5,964
Contribution Margin %	55.6%	60.1%	40.8%	46.2%	51.9%
Recurrent Fees %	49%	-	51%	26%	42%
Proprietary Products Revenues	7,011	369	1,136	1,127	9,633
Proprietary Products Revenues	100%	88%	95%	39%	83.8%



Environment

CO2 emissions

Thanks to Maps Habitat project, we have reduced commuting by 70% and from 2021 we rent only hybrid cars

Responsible consumption

Our purchase and dispose of policies are based on the environmental impact



Social

Employees

We have launched projects to improve our people quality of life

Our commitment is recognised, we have been included among the 105 Italian companies to have a 5W- welfare rating by Generali Italia

Support for social initiatives

In particular on training, hospitality, inclusion.



Governance

Compliance with the best practices of large public companies

Number of Independent directors, corporate governance procedures

Process Control

Adoption of an organisational model designed to prevent crimes or any attempts to commit crimes and to reduce outside-of-the-ethic-code conducts


In 2022 the sustainability report will be audited

What we are going to do





We support our customers
in their processes of
Digital Transformation



Offering solutions that:
Extract Value form Data
Help Create new Business Models

Growth Strategy – Our goals

Focus on Growth Trends

R&D investments on trends that we are already following and sensibility on new near trends

Business Model based on Proprietary Products

Maintain an **80% of revenues** based on **Proprietary Products** – for business scalability and high margins - and **20%** on **bespoke solutions** – for qualified relationships with first tier customers and to keep learning by working in complex scenarios

Acquire Companies

Focusing on **Healthcare, Energy and ESG**

Improve our current Solution Market Penetration

Leveraging on **the growth of the trends** that we are following



MAPS
SHARING KNOWLEDGE

www.mapsgroup.it

Via Paradigna 38/A,
43122 Parma (PR), Italy



MAPS
SHARING KNOWLEDGE

ANNEX

Focus - SCS Computers acquisition

Offering

Focalization on Healthcare Clinical area

- Analysis Lab
- Emergency
- Pathological Anatomy

Business Model

Based on **Proprietary Products**

- High recurrent fees (2020: 75%)
- Long term contracts (e.g 7 years contract with Regione Marche)

Financial performance

Before acquisition (2019)

Revenues: € 1.6 mln

EBITDA: € 0.5 mln

Contribution margin: > 50%

Transactions

100% acquisition

Price: € 4.0 mln

Payment in 2 tranches:

€ 2.5 mln at deal closing

€ 1.5 mln in 2025

(5 years form deal closing)

Synergies



Laboratories are one of the most important access points to hospitals; we will **integrate SCS solutions** with patient journey offer line



SCS solutions data will be **converted into Smart Data**, allowing Maps significantly increase the support to decision makers



Zerocoda & Mr You integrated with SCS Analysis Lab in Regione Marche



EBITDAx: 6.1

Offering

Focalization on Healthcare

- Clinical Area
- HR Management for Healthcare
- No overlap with current Healthcare offer lines

Business Model

Based on **Proprietary Products**

- High recurrent fees (2021: 52%)
- Loyal Customers

Financial performance

Before acquisition (2020)

Revenues: € 3.2 mln

EBITDA: € 0.9 mln

Contribution margin: 48%

Transactions

100% acquisition

Price: € 5.3 mln

€ 0.9 mln: Maps shares at € 4.36 per share

Cash payment in 2 tranches:

€ 2.9 mln at deal closing

€ 1.5 mln in 2024

Synergies



Thanks to IASI acquisition, the healthcare offer is much more complete, increasing Maps Group opportunities as principal vendor for hospitals



IASI solutions data will be converted into Smart Data, allowing Maps significantly increase the support to decision makers

Iasi and Maps Healthcare sales teams are integrated and are working on new opportunities that we forecast to realize during 2022.



EBITDAx: 5.6



Achievements - 2021 Results

€/1,000	2021	2020
Total Revenues	21,527	17,930
Internally generated fixed assets	1,997	1,688
Production Value	23,524	19,618
Operating Costs	(18,946)	(16,213)
EBITDA	5,028	3,405
Amortization & Depreciation	(2,595)	(2,273)
Not recurring costs	(224)	(295)
EBIT	2,210	837
Financial Management & Subsidiaries	(154)	329
EBT	2,056	1,166
Tax	432	(151)
Net Profit	2,488	1,014

€/1,000	2021	2020
Fixed Assets	18,936	15,880
Inventory	3,601	3,469
Receivables	9,901	7,404
Payables	(2,489)	(2,092)
Operating Working Capital	11,013	8,780
Other Current assets & liability	(1,246)	(1,774)
Net Working Capital	9,767	7,006
Total Funds	(5,712)	(4,685)
Net Capital Invested	22,991	18,201
Shareholders' Equity	18,083	11,193
Long Term Debt	12,189	11,541
Short Term Debt	3,815	2,642
Cash	(11,097)	(7,175)
Net Financial Position	4,908	7,008
Total resources of financing	22,991	18,201

Total Revenues



Recurrent revenues from fees



EBITDA



NFP



Cash





Achievements - 2021 Results

€/1,000	Healthcare	ESG	Large Enterprise	2021
Recurrent Fees	4,748	0,636	1,767	7,151
Services	6,876	1,076	6,016	13,968
Others Revenue	0,152	0,065	0,192	0,408
Total Revenues	11,777	1,776	7,975	21,527
Personnel Costs	(3,306)	(0,816)	(3,981)	(8,103)
Direct Services Costs	(1,904)	(0,119)	(0,958)	(2,981)
Total Operating Costs	(5,210)	(0,935)	(4,939)	(11,084)
Commercial Costs	(1,386)	(0,300)	(0,595)	(2,281)
R&D Costs	(1,212)	(0,271)	(0,514)	(1,997)
Internally Generated Fixed Assets	1,212	0,271	0,514	1,997
Administrative Costs	(1,611)	(0,232)	(1,292)	(3,135)

EBITDA	3,569	0,310	1,149	5,028
EBITDA Margin	30.3%	17.4%	14.4%	23.4%
Contribution Margin	6,414	0,776	2,844	10,035
Contribution Margin %	55.2%	45.4%	36.5%	47.5%
Recurrent Fees %	41%	37%	23%	34%
Proprietary Solutions Revenues	11,625	1,711	1,840	15,176
Proprietary Solutions Revenues	100%	100%	24%	72%



MAPS
SHARING KNOWLEDGE

www.mapsgroup.it

Via Paradigna 38/A,
43122 Parma (PR), Italy